Lonza and Agennix Sign Development and Manufacturing Deal for Production of Talactoferrin
Lonza will manufacture talactoferrin at its microbial facility in Kouřim, Czech Republic
12-Apr-2012 -
Lonza and Agennix AG announced an agreement for the production of Agennix’s first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC). Under the agreement, Lonza will produce commercial ...
immunotherapies
Lonza
talactoferrin